Cross talk between beta(1) and alpha(V) integrins: beta(1) affects beta(3) mRNA stability.
There is increasing evidence that a fine-tuned integrin cross talk can generate a high degree of specificity in cell adhesion, suggesting that spatially and temporally coordinated expression and activation of integrins are more important for regulated cell adhesive functions than the intrinsic specificity of individual receptors. However, little is known concerning the molecular mechanisms of integrin cross talk. With the use of beta(1)-null GD25 cells ectopically expressing the beta(1)A integrin subunit, we provide evidence for the existence of a cross talk between beta(1) and alpha(V) integrins that affects the ratio of alpha(V)beta(3) and alpha(V)beta(5) integrin cell surface levels. In particular, we demonstrate that a down-regulation of alpha(V)beta(3) and an up-regulation of alpha(V)beta(5) occur as a consequence of beta(1)A expression. Moreover, with the use of GD25 cells expressing the integrin isoforms beta(1)B and beta(1)D, as well as two beta(1) cytoplasmic domain deletion mutants lacking either the entire cytoplasmic domain (beta(1)TR) or only its "variable" region (beta(1)COM), we show that the effects of beta(1) over alpha(V) integrins take place irrespective of the type of beta(1) isoform, but require the presence of the "common" region of the beta(1) cytoplasmic domain. In an attempt to establish the regulatory mechanism(s) whereby beta(1) integrins exert their trans-acting functions, we have found that the down-regulation of alpha(V)beta(3) is due to a decreased beta(3) subunit mRNA stability, whereas the up-regulation of alpha(V)beta(5) is mainly due to translational or posttranslational events. These findings provide the first evidence for an integrin cross talk based on the regulation of mRNA stability.
Retta
S F
SF
Department of Genetics, Biology, and Biochemistry, University of Torino, 10126 Torino, Italy. francesco.ritto@unito.it
Cassarà
G
G
D'Amato
M
M
Alessandro
R
R
Pellegrino
M
M
Degani
S
S
De Leo
G
G
Silengo
L
L
Tarone
G
G
D000818:Animals; D015703:Antigens, CD / Q000378:metabolism*; D000954:Antigens, Surface / Q000378:metabolism; D002448:Cell Adhesion / Q000502:physiology; D002478:Cells, Cultured / Q000166:cytology / Q000378:metabolism; D003593:Cytoplasm / Q000378:metabolism; D005347:Fibroblasts / Q000166:cytology / Q000378:metabolism; D039564:Integrin alphaV; D039641:Integrin beta Chains; D019012:Integrin beta1 / Q000378:metabolism*; D039661:Integrin beta3; D016023:Integrins / Q000819:agonists / Q000187:drug effects / Q000378:metabolism*; D051379:Mice; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism*; D017434:Protein Structure, Tertiary / Q000502:physiology; D020871:RNA Stability / Q000502:physiology*; D012333:RNA, Messenger / Q000378:metabolism*; D019030:Receptors, Vitronectin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013347:Subcellular Fractions / Q000378:metabolism; D015854:Up-Regulation / Q000187:drug effects
D015703:Antigens, CD; D000954:Antigens, Surface; D039564:Integrin alphaV; D039641:Integrin beta Chains; D019012:Integrin beta1; D039661:Integrin beta3; D016023:Integrins; D010980:Platelet Membrane Glycoproteins; D012333:RNA, Messenger; D019030:Receptors, Vitronectin; C064660:integrin alphaVbeta5; C084344:integrin beta5